President Donald Trump is targeting prescription drug costs. He signed a wide-ranging Trump drug price executive order. This order directs the Department of Health and Human Services (HHS). HHS will pursue changes to Medicare’s drug price negotiations. This move signals a potential shift favoured by drugmakers. The pharmaceutical industry has lobbied against negotiation timelines. Currently, complex biologics are negotiated after…